Main Navigation Tabs Menu

The content of this presentation is provided to an audience of international healthcare professionals for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.

At the moment of publication, the compound presented has been only approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.

The American Society of Nephrology
Kidney Week 2023 2-5 November 2023

Scientific publications at ASN Kidney Week 2023.

Thank you for your interest! Please see below to download the posters/presentations at ASN 2023. Presentations, Videos and Posters will be available following the presentation at the congress.

Some of the links to view the Presentations or Posters will link to the official ASN 2023 web page. You may need to be a registered delegate and logged in the respective platform to view the content.

Finerenone

November 4, 2023 from 10:00 AM to 12:00 PM
End-stage kidney disease-free survival time in patients with CKD and T2D in FIDELITY

Session: Diabetic Kidney Disease: Clinical - II [PO0702-2] Lead author: Ajay Singh

November 3, 2023 from 10:00 AM to 12:00 PM
Design and Baseline Characteristics of the FIND-CKD Trial: Efficacy of Finerenone on Kidney Disease Progression in People with Non-Diabetic Chronic Kidney Disease (CKD)

Session: CKD Interventions: Trials and Quality Improvement [PO2302-2] Lead author: Hiddo Heerspink

November 3, 2023 from 10:00 AM to 12:00 PM
Rationale and design of a Phase 3 registration trial investigating finerenone in participants with chronic kidney disease and type 1 diabetes using a UACR endpoint (FINE-ONE)

Lead author: Hiddo Heerspink

November 4, 2023 from 10:00 AM to 12:00 PM
Interim Results From FINE-REAL: A Prospective Study Providing Insights Into the Use of Finerenone in Routine Clinical Settings

Session: Diabetic Kidney Disease: Clinical - II [PO0702-2] Lead author: Susanne B. Nicholas

November 4, 2023 from 10:00 AM to 12:00 PM
Early use and effectiveness of finerenone in US patients with chronic kidney disease and type 2 diabetes - a FOUNTAIN platform analysis

Session: Diabetic Kidney Disease: Clinical - II [PO0702-2]Lead author: Nikolaus Oberprieler

Finerenone: a new approach to kidney protection in patients with type 2 diabetes


Saturday 17 June, 2023 | 13.35 - 13.45 CET | On Demand
Non-steroidal MRAs: A new pillar of treatment for cardiorenal protection in CKD and T2D
The symposium offers a unique opportunity to gain an overview of the most recent guideline updates related to CKD and T2D and the need for a comprehensive and holistic approach to the patient management. To discuss the use of the ‘pillar approach’ to manage CKD in T2D and how to use finerenone in clinical practice based on expert experience. To highlight the relevance of the urgency to treat CKD in T2D to improve cardiorenal outcomes.

Faculty: Giuseppe Grandaliano (chair), Beatriz Fernandez, Christoph Wanner, Rajiv Agarwal Session: Industry Sponsored Symposium Speaker: Rajiv Agarwal

Play Icon

View Video

17/06/2023 - 8:30 - 9:45 CEST

FINEGUST- Japan; characteristics of medication-initiator cohorts of patients with chronic kidney disease and type 2 diabetes in Japan - a report from FOUNTAIN platform

Session type: focused oral presentation ROOM 6 Presenter: Yuichiro Yano

16/06/2023 - 08:30-09:45 CEST

Validation of a CKD progression risk prediction model in the FIDELITY trial population

Session type: poster / abstract Presenter: Navdeep Tangri

17/06/2023 - 14:45 - 16:00 CEST

REKA: Incidence and frequencies of hyperkalemia in patients with chronic kidney disease: a retrospective database study from US clinical care

Session type: focused oral presentation ROOM 1 Presenter: Van Boemmel-Wegmann